Inex/Enzon's Marqibo Accelerated Approval Application "Not Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA recommends additional randomized studies comparing Marqibo to other chemotherapy agents; the agency also cites CMC deficiencies. The "not approvable" letter follows a negative committee review for the non-Hodgkin's lymphoma therapy.
You may also be interested in...
Talon Marqibo’s Fate May Hang On Adjudication Of Trial Subjects
With Talon offering a single Phase II trial to support its NDA for Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia, everything may hinge on the disagreement between the sponsor and FDA over whether eight patients or 13 out of 65 experienced some type of complete response.
Hana Braces For Additional Zensana Research
Problem discovered in commercialization ramp-up of the antiemetic spray has company anticipating additional studies, more FDA review time.
Hana Braces For Additional Zensana Research
Problem discovered in commercialization ramp-up of the antiemetic spray has company anticipating additional studies, more FDA review time.